Molecular Partners Publishes MP0317 Clinical Data
Written by Emily J. Thompson, Senior Investment Analyst
Updated: May 01 2026
0mins
Molecular Partners announced the publication of Phase 1 clinical data in Nature Cancer demonstrating the potential of the tumor-localized CD40 agonist, MP0317, to modulate the tumor microenvironment. MP0317 is designed to activate immune cells specifically within the TME by anchoring to fibroblast activation protein, which is expressed in high amounts in the stroma of various solid tumors. This tumor-localized approach has the potential to deliver greater efficacy with fewer side effects compared to systemic CD40-targeting therapies. The peer-reviewed paper published by Steehgs et al., entitled "Tumor-localized CD40 agonism with MP0317, a FAPxCD40 DARPin, reprograms the tumor microenvironment - results of a Phase 1 monotherapy study", reports the positive results from the completed Phase 1 dose escalation study of MP0317. The comprehensive biomarker data confirm proof-of-mechanism for MP0317, including tumor-localized activation of the CD40 pathway and evidence of TME remodeling in patients with advanced solid tumors. MP0317 displayed a favorable safety profile up to the highest tested dose and serum pharmacokinetics confirmed suitability for dosing either weekly or every three weeks. Of the 46 patients in the study, one patient achieved an unconfirmed partial response and 14 patients stable disease in this heterogeneous population with advanced diseases. Data were presented at the 2024 Annual Meetings of the American Society of Clinical Oncology and of the Society for Immunotherapy of Cancer.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy MOLN?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on MOLN
Wall Street analysts forecast MOLN stock price to rise
2 Analyst Rating
2 Buy
0 Hold
0 Sell
Moderate Buy
Current: 3.870
Low
8.00
Averages
10.00
High
12.00
Current: 3.870
Low
8.00
Averages
10.00
High
12.00
About MOLN
Molecular Partners AG is a Switzerland-based clinical-stage biotech company developing DARPin (Designed Ankyrin Repeat Proteins) a new class of custom-built protein therapeutics based on natural binding proteins that open a new dimension of multi-functionality and multi-target specificity in drug design. The Company has formed partnerships with leading pharmaceutical companies to advance DARPin therapeutics , and has compounds in various stages of clinical and preclinical development across multiple therapeutic areas.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Molecular Partners Initiates DLL3-Targeting Therapy Study
- Clinical Trial Launch: Molecular Partners, in collaboration with Orano Med, has initiated a Phase 1/2a study of MP0712 at five centers in the US, marking a significant advancement in DLL3-targeted therapy that could offer new treatment options for small cell lung cancer patients.
- Dose Escalation Study: As the first Radio-DARPin candidate, MP0712 is undergoing a dose escalation study with up to four levels, and the first patient has entered repeat dosing, with initial data expected in 2026 to further validate its clinical safety profile.
- Targeted Therapy Potential: DLL3 is expressed in over 85% of small cell lung cancer tumors, and the development of MP0712 aims to leverage its high expression in tumors to provide treatment options for various aggressive neuroendocrine tumors, indicating significant market potential.
- Future Data Outlook: Initial data is anticipated within the coming months, while comprehensive safety and efficacy data is expected in 2027, laying the groundwork for the development of subsequent Radio-DARPin candidates.
See More
Molecular Partners and Orano Med Initiate DLL3-Targeting Therapy Clinical Trial
- Clinical Trial Launch: Molecular Partners and Orano Med have initiated a clinical trial for DLL3-targeting MP0712 in the US, with the first patient dosed, marking a critical step in the development of this therapy aimed at providing new treatment options for small cell lung cancer patients.
- Targeting Mechanism: MP0712 targets the tumor-associated protein DLL3, utilizing 212Pb as a therapeutic payload, with DLL3 expressed in over 85% of small cell lung cancer tumors, highlighting its significance in enhancing treatment efficacy.
- Data Release Timeline: Initial data is expected to be reported in 2026, while comprehensive efficacy data is anticipated in 2027, which will provide crucial insights for future clinical applications and may drive the development of additional Radio-DARPin candidates.
- Multicenter Recruitment: Currently, five centers in the US are actively recruiting patients using a
See More
Molecular Partners Announces Clinical Trial Progress
- Clinical Trial Progress: Molecular Partners will present the clinical trial progress of its MP0712 for small cell lung cancer at the 2026 American Society of Clinical Oncology Annual Meeting, indicating the company's ongoing innovation in cancer treatment.
- Targeted Therapy Candidate: MP0712 is a 212Pb-based Radio-DARPin therapy targeting DLL3, which is expressed in over 85% of small cell lung cancer tumors, showcasing its potential to provide new treatment options for patients.
- Multicenter Study Recruitment: The US multicenter Phase 1/2a study of MP0712 is actively recruiting patients to assess safety and determine a recommended Phase 2 dose, with initial clinical data expected to be shared in 2026, further advancing product development.
- International Collaboration: The strategic partnership with Orano Med combines expertise to accelerate the clinical development of MP0712, reflecting the company's leadership and market potential in the field of radiopharmaceutical therapy.
See More
Molecular Partners Q1 Earnings Miss Expectations
- Earnings Performance: Molecular Partners reported a Q1 GAAP EPS of -$0.67, missing expectations by $0.25, indicating challenges in profitability that may affect investor confidence.
- Cash Position: As of March 31, 2026, the company holds approximately $365.6 million in cash, cash equivalents, and marketable securities, ensuring sufficient operational funding for the coming years.
- Operational Outlook: Based on current operating assumptions, the company anticipates that its cash and equivalents will support planned operations into the second quarter of 2029, reflecting a degree of financial stability.
- Historical Performance Review: In Q4 2025, Molecular Partners reported a GAAP EPS of -CHF1.65, beating expectations by CHF0.32, indicating some volatility in the company's past financial performance.
See More
Molecular Partners to Present at Scientific Conferences
- Conference Schedule: Molecular Partners will present its clinical-stage Radio-DARPin candidate MP0712 at the NIH National Cancer Institute Small Cell Lung Cancer Consortium Meeting on May 6-7, 2026, showcasing its potential in targeted radiotherapy for small cell lung cancer.
- Clinical Progress Presentation: At the 22nd Annual PEGS Boston from May 11-15, 2026, the company will discuss advancements in Radio-DARPin therapeutics, from preclinical insights to clinical development, highlighting its innovative applications in cancer treatment.
- First Human Data Sharing: The company will share first-in-human data on MP0712 at the Antibody & Engineering Therapeutics conference on May 29, 2026, exploring its applications in targeted alpha therapy and furthering the development of future candidates.
- Commitment to Technological Innovation: Molecular Partners is dedicated to developing next-generation DARPin therapeutics aimed at addressing medical challenges that other treatment modalities cannot readily tackle, demonstrating its leadership in the biotechnology sector.
See More
Positive Phase 1 Data for MP0317 in Cancer Treatment
- Clinical Trial Results: MP0317 demonstrated a favorable safety profile in a Phase 1 trial, with 1 out of 46 patients achieving an unconfirmed partial response and 14 patients showing stable disease, indicating its potential in treating advanced cancers.
- Tumor Microenvironment Modulation: By targeting fibroblast activation protein (FAP) to locally activate the CD40 pathway, MP0317 may enhance efficacy while reducing systemic toxicity, showcasing its significant role in tumor microenvironment remodeling.
- Phase 2 Clinical Study Initiation: An investigator-initiated Phase 2 trial for cholangiocarcinoma has commenced, aiming to enroll 75 patients to compare the effects of MP0317 combined with standard treatment, with the goal of improving the 12-month progression-free survival rate.
- Future Development Prospects: Researchers believe that combining MP0317 with immune checkpoint inhibitors will further enhance its clinical benefits, supporting its potential application in cancer treatment.
See More
Molecular Partners Initiates DLL3-Targeting Therapy Study
- Clinical Trial Launch: Molecular Partners, in collaboration with Orano Med, has initiated a Phase 1/2a study of MP0712 at five centers in the US, marking a significant advancement in DLL3-targeted therapy that could offer new treatment options for small cell lung cancer patients.
- Dose Escalation Study: As the first Radio-DARPin candidate, MP0712 is undergoing a dose escalation study with up to four levels, and the first patient has entered repeat dosing, with initial data expected in 2026 to further validate its clinical safety profile.
- Targeted Therapy Potential: DLL3 is expressed in over 85% of small cell lung cancer tumors, and the development of MP0712 aims to leverage its high expression in tumors to provide treatment options for various aggressive neuroendocrine tumors, indicating significant market potential.
- Future Data Outlook: Initial data is anticipated within the coming months, while comprehensive safety and efficacy data is expected in 2027, laying the groundwork for the development of subsequent Radio-DARPin candidates.
See More
Molecular Partners and Orano Med Initiate DLL3-Targeting Therapy Clinical Trial
- Clinical Trial Launch: Molecular Partners and Orano Med have initiated a clinical trial for DLL3-targeting MP0712 in the US, with the first patient dosed, marking a critical step in the development of this therapy aimed at providing new treatment options for small cell lung cancer patients.
- Targeting Mechanism: MP0712 targets the tumor-associated protein DLL3, utilizing 212Pb as a therapeutic payload, with DLL3 expressed in over 85% of small cell lung cancer tumors, highlighting its significance in enhancing treatment efficacy.
- Data Release Timeline: Initial data is expected to be reported in 2026, while comprehensive efficacy data is anticipated in 2027, which will provide crucial insights for future clinical applications and may drive the development of additional Radio-DARPin candidates.
- Multicenter Recruitment: Currently, five centers in the US are actively recruiting patients using a
See More
Molecular Partners Announces Clinical Trial Progress
- Clinical Trial Progress: Molecular Partners will present the clinical trial progress of its MP0712 for small cell lung cancer at the 2026 American Society of Clinical Oncology Annual Meeting, indicating the company's ongoing innovation in cancer treatment.
- Targeted Therapy Candidate: MP0712 is a 212Pb-based Radio-DARPin therapy targeting DLL3, which is expressed in over 85% of small cell lung cancer tumors, showcasing its potential to provide new treatment options for patients.
- Multicenter Study Recruitment: The US multicenter Phase 1/2a study of MP0712 is actively recruiting patients to assess safety and determine a recommended Phase 2 dose, with initial clinical data expected to be shared in 2026, further advancing product development.
- International Collaboration: The strategic partnership with Orano Med combines expertise to accelerate the clinical development of MP0712, reflecting the company's leadership and market potential in the field of radiopharmaceutical therapy.
See More
Molecular Partners Q1 Earnings Miss Expectations
- Earnings Performance: Molecular Partners reported a Q1 GAAP EPS of -$0.67, missing expectations by $0.25, indicating challenges in profitability that may affect investor confidence.
- Cash Position: As of March 31, 2026, the company holds approximately $365.6 million in cash, cash equivalents, and marketable securities, ensuring sufficient operational funding for the coming years.
- Operational Outlook: Based on current operating assumptions, the company anticipates that its cash and equivalents will support planned operations into the second quarter of 2029, reflecting a degree of financial stability.
- Historical Performance Review: In Q4 2025, Molecular Partners reported a GAAP EPS of -CHF1.65, beating expectations by CHF0.32, indicating some volatility in the company's past financial performance.
See More
Molecular Partners to Present at Scientific Conferences
- Conference Schedule: Molecular Partners will present its clinical-stage Radio-DARPin candidate MP0712 at the NIH National Cancer Institute Small Cell Lung Cancer Consortium Meeting on May 6-7, 2026, showcasing its potential in targeted radiotherapy for small cell lung cancer.
- Clinical Progress Presentation: At the 22nd Annual PEGS Boston from May 11-15, 2026, the company will discuss advancements in Radio-DARPin therapeutics, from preclinical insights to clinical development, highlighting its innovative applications in cancer treatment.
- First Human Data Sharing: The company will share first-in-human data on MP0712 at the Antibody & Engineering Therapeutics conference on May 29, 2026, exploring its applications in targeted alpha therapy and furthering the development of future candidates.
- Commitment to Technological Innovation: Molecular Partners is dedicated to developing next-generation DARPin therapeutics aimed at addressing medical challenges that other treatment modalities cannot readily tackle, demonstrating its leadership in the biotechnology sector.
See More
Positive Phase 1 Data for MP0317 in Cancer Treatment
- Clinical Trial Results: MP0317 demonstrated a favorable safety profile in a Phase 1 trial, with 1 out of 46 patients achieving an unconfirmed partial response and 14 patients showing stable disease, indicating its potential in treating advanced cancers.
- Tumor Microenvironment Modulation: By targeting fibroblast activation protein (FAP) to locally activate the CD40 pathway, MP0317 may enhance efficacy while reducing systemic toxicity, showcasing its significant role in tumor microenvironment remodeling.
- Phase 2 Clinical Study Initiation: An investigator-initiated Phase 2 trial for cholangiocarcinoma has commenced, aiming to enroll 75 patients to compare the effects of MP0317 combined with standard treatment, with the goal of improving the 12-month progression-free survival rate.
- Future Development Prospects: Researchers believe that combining MP0317 with immune checkpoint inhibitors will further enhance its clinical benefits, supporting its potential application in cancer treatment.
See More
